Abstract
The study aims to assess the expression of serum miRNA-142_3p and miRNA-142_5p in IBD patients and its correlation with disease extent, activity and severity. It was performed on 35 patients with ulcerative colitis (UC), 35 patients with Crohn’s disease (CD) and 30 healthy controls. Serum miRNA-142 expression was assessed using reverse transcriptase quantitative real time PCR (RT-qPCR), and then correlated with that of a group of 30 healthy subjects. It was also correlated with disease extent and disease activity and severity indices (CDAI, Montreal classification, Partial Mayo score). The patients’ group showed mean serum miR-142_3p expression of 2.69±1.96 for CD, 1.66±0.90 for UC and 1.25±0.91 for the control group and serum miR-142_5p expression of 2.42±2.08 for CD, 1.61±1.12 for UC and 1.21±0.78 for the control group with a significant difference between groups. Conclusion: The expression of miR-142_3p and miR-142_5p was significantly higher in patients with CD compared to patients with UC and the control group.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
